Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype

BACKGROUND: Glioblastoma (GBM) is the most common and most aggressive primary malignant brain tumor. Standard-of-care treatment involves maximal surgical resection of the tumor followed by radiation and chemotherapy (temozolomide [TMZ]). The 5-year survival rate of patients with GBM is <10%, a co...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Teng, Jian, Hejazi, Seyedali, Hiddingh, Lotte, Carvalho, Litia, de Gooijer, Mark C, Wakimoto, Hiroaki, Barazas, Marco, Tannous, Marie, Chi, Andrew S, Noske, David P, Wesseling, Pieter, Wurdinger, Thomas, Batchelor, Tracy T, Tannous, Bakhos A
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2018
Предметы:
Basic and Translational Investigations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892145/
https://ncbi.nlm.nih.gov/pubmed/29099956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox198
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы